TP53 and undifferentiated carcinoma: Type II ovarian cancer, which includes high‐grade serous carcinoma, undifferentiated carcinoma and sarcoma, often has mutations in BRCA1 or BRCA2, and TP53, which is consistent with our results (Table 1).